HOUSTON, Dec. 3, 2019 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) a biotechnology company
specializing in the development of novel treatments for brain
tumors, today announced that John
Climaco, Chief Executive Officer of CNS Pharmaceuticals,
will be participating in the 12th Annual LD Micro Main Event
Conference in Los Angeles, CA.
Event:
|
12th Annual LD Micro
Main Event Conference
|
Format:
|
Presentation &
1x1 Meetings
|
Date:
|
Tuesday, December 10,
2019
|
Time:
|
4:20pm PT
|
Location:
|
Luxe Sunset Boulevard
Hotel, Los Angeles, CA
|
About Berubicin
Berubicin is an anthracycline, a class
of drugs among the most powerful chemotherapy drugs and effective
against more types of cancer than any other class of
chemotherapeutic agents. Anthracyclines are designed to damage the
DNA of targeted cancer cells by interfering with the action of the
topoisomerase II, a critical enzyme enabling cell proliferation.
Berubicin was developed at the MD Anderson Cancer Center (MDACC),
the world's largest cancer research facility. Berubicin appeared to
demonstrate one Durable Complete Response in a Phase I human
clinical trial conducted by a prior developer.
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is
a biotechnology company specializing in the development of novel
treatments for primary and metastatic brain and central nervous
system tumors. Its lead candidate Berubicin is for the treatment of
glioblastoma, a type of brain cancer currently considered
incurable, as well as pancreatic and ovarian cancers, and
lymphomas. The Company entered into an IP agreement with Houston
Pharmaceuticals, Inc. and a Purchase Agreement with Reata
Pharmaceuticals Inc. For more information, visit
www.cnspharma.com
View original
content:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-participate-in-12th-annual-ld-micro-main-event-conference-300967894.html
SOURCE CNS Pharmaceuticals, Inc.